41 recruiting, 24 not yet recruiting, 8 completed, 6 active not recruiting. 32 Phase 2, 17 Not applicable, 9 Phase 1, 3 Phase 3, 2 Phase 4.
Follow HCC - Hepatocellular Carcinoma: new trials by email Literature Review of HCC - Hepatocellular Carcinoma trials Research Report on HCC - Hepatocellular Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome Shuganhuazhuo Formula, Targeted therapy, Immunotherapy - HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine | Phase 2 | Not yet recruiting | Xiang-Qian | 120 | 2027-09-01 | 2026-08-27 |
| A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular Carcinoma Ivonescimab - Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | MedSIR | 44 | 2027-03-01 | 2026-11-04 |
| Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 35 | 2026-10-01 | 2026-09-15 |
| Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma SYS6090 Injection + Bevacizumab Injection, SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection, Bevacizumab Injection + Sintilimab Injection - HCC - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 288 | 2026-09-30 | 2026-08-12 |
| Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 20 | 2026-09-01 | 2026-09-03 |
| Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function Liver Cirrhosis, HCC - Hepatocellular Carcinoma | Recruiting | Northern Jiangsu People's Hospital | 30 | 2026-08-02 | 2026-09-10 | |
| Real-world Insight Into Systemic Therapies for HCC: Single-center Study HCC - Hepatocellular Carcinoma | Recruiting | Mansoura University | 1000 | 2026-08-01 | 2026-09-10 | |
| Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma (HCC) Prior to Liver Transplantation Stereotactic body radiation therapy (SBRT) in addition to TACE prior to liver transplantation, The patients will receive two procedures of TACE prior to liver transplantation - HCC - Hepatocellular Carcinoma | Not applicable | Recruiting | AIO-Studien-gGmbH | 44 | 2026-07-28 | 2026-11-09 |
| A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma IMM2510, IMM27M - HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | 50 | 2026-07-23 | 2026-07-07 |
| SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma Stereotactic Body Radiation Therapy (SBRT), QL1706 - HCC - Hepatocellular Carcinoma | Phase 4 | Not yet recruiting | Hebei Medical University Fourth Hospital | 36 | 2026-07-01 | 2026-06-25 |
| Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI eparlitozoviril, Control group - HCC - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-06-12 | 2026-06-18 |
| A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence Tislelizumab, Lenvatinib - HCC - Hepatocellular Carcinoma | Phase 3 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 198 | 2026-06-09 | 2026-08-05 |
| Social Determinants of Health HCC Trial Social Determinants of Health Program, Patient Navigation - HCC - Hepatocellular Carcinoma | Not applicable | Not yet recruiting | University of Southern California | 75 | 2026-06-01 | 2026-05-05 |
| A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk Iparomlimab and Tuvonralimab - HCC - Hepatocellular Carcinoma, Iparomlimab and Tuvonralimab Injection | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-05-30 | 2026-04-07 |
| A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors Camrelizumab (anti-PD-1 inhibitor), Apatinib Mesylate Tablets, FOLFOX-HAIC - HCC - Hepatocellular Carcinoma | Not applicable | Not yet recruiting | Henan Cancer Hospital | 208 | 2026-05-25 | 2026-06-01 |
| The DoHAICs Study Expansion Phase Donafenib, sintilimab, HAIC - HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 90 | 2026-05-20 | 2026-05-13 |
| Defining the Ablative Dose for Y-90 TARE Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres - HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Northwestern University | 30 | 2026-05-15 | 2026-09-15 |
| A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma Firsekibart + Tislelizumab + Lenvatinib - HCC - Hepatocellular Carcinoma, TP53 Gene Mutation | Not applicable | Not yet recruiting | Tongji Hospital | 25 | 2026-05-01 | 2026-04-17 |
| Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin Tislelizumab, Lenvatinib - HCC - Hepatocellular Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-04-30 | 2026-04-09 |
| Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence Liver-in-cube testing - HCC - Hepatocellular Carcinoma | Recruiting | The University of Hong Kong | 20 | 2026-04-13 | 2026-09-24 |
Showing 20 of 84. Sign in to see all of them.
Carcinoma, Hepatocellular (84) · Carcinoma, Non-Small-Cell Lung (5) · Neoplasms (5) · Melanoma (4) · Colorectal Neoplasms (3) · Endometrial Neoplasms (3) · Fibrosis (3) · Liver Neoplasms (3) · Diabetes Mellitus (2) · Liver Cirrhosis (2) · Pancreatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Cholangiocarcinoma (1) · Fatty Liver (1)
Adenocarcinoma (84) · Carcinoma (84) · Digestive System Diseases (84) · Digestive System Neoplasms (84) · Liver Diseases (84) · Neoplasms by Histologic Type (84) · Neoplasms by Site (84) · Neoplasms, Glandular and Epithelial (84) · Liver Neoplasms (81) · Neoplasms (79) · Pathological Conditions, Signs and Symptoms (10) · Pathologic Processes (7) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Respiratory Tract Neoplasms (6)
lenvatinib (9) · tislelizumab (7) · Bevacizumab (5) · atezolizumab (5) · sintilimab (5) · Radiosurgery (4) · durvalumab (3) · tremelimumab (3) · Immunotherapy (2) · Radiotherapy (2) · apatinib (2) · camrelizumab (2) · donafenib (2) · pembrolizumab (2) · Amino Acids, Branched-Chain (1)
Tianjin Medical University Cancer Institute and Hospital (7) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (3) · Tongji Hospital (3) · Zhongda Hospital (3) · Beijing Tsinghua Chang Gung Hospital (2) · Chang Gung Memorial Hospital (2) · Chinese University of Hong Kong (2) · Henan Cancer Hospital (2) · Mansoura University (2) · Northern Jiangsu People's Hospital (2) · Shanghai Zhongshan Hospital (2) · The University of Hong Kong (2) · West China Hospital (2) · AIO-Studien-gGmbH (1) · Ain Shams University (1)
China (36) · Egypt (4) · Hong Kong (4) · Italy (4) · France (3) · Taiwan (3) · United States (3) · Germany (2) · Vietnam (2) · Canada (1) · Netherlands (1) · Pakistan (1) · Poland (1) · Turkey (Türkiye) (1)
Haibo Shao (2) · Ali M Hussein, PhD (1) · Chuan Pang (1) · Cristina Mosconi, MD (1) · Fatih Selcukbiricik, MD (1) · Gerald Prager, MD (1) · Guo-Qing Jiang (1) · Hao Feng, Ph.D.,MD (1) · Hongxia Wang, Doctorate (1) · Jimmy CT Lai, MB ChB (1) · Li Bing, PhD. (1) · Michael T Dill, PhD (1)
PMID 11858978, PMID 12806613, PMID 15043519, PMID 21874260, PMID 30082086, PMID 31974491, PMID 31989907, PMID 33334813, PMID 34087115, PMID 34256416, PMID 34706232, PMID 34801630, PMID 35114133, PMID 35294089, PMID 36753026, PMID 36997828, PMID 37059069, PMID 37099632, PMID 37316719, PMID 37731001, PMID 38039993, PMID 38305472, PMID 38453934, PMID 38678378, PMID 38959326, PMID 39148179, PMID 39801235, PMID 39825376, PMID 39915765, PMID 40930561, PMID 40930564, PMID 41357510, PMID 42185926, PMID 42330996, PMID 42486514